+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 34 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the use of pemigatinib for adults with advanced or metastatic pancreatic cancer that has spread locally or to distant parts of the body. This study focuses on patients whose cancer has specific abnormal changes in the FGFR gene, which can promote cancer growth. The goal is to see if pemigatinib can block these abnormal genes to stop tumor growth and improve quality of life. Participants take pemigatinib orally once daily for 14 days in each 21-day cycle, continuing as long as the cancer does not worsen or side effects are manageable. During the study, patients undergo blood tests, CT andor MRI scans, and optical coherence tomography OCT. Additional scans like whole body bone scans and eye exams may be performed if needed. After treatment, patients are followed up 30 days later and then every 4 months for one year. Throughout the study, researchers assess tumor response using imaging and blood tests, including monitoring cell-free DNA to track response and resistance. They measure overall response rate up to 24 months and evaluate progression-free survival, disease control, overall survival, and side effects up to 12 months. Safety and tolerability are closely monitored, and patients overall health and treatment effects are regularly checked to understand the impact of pemigatinib.

Age: 18Years +All GendersPhase 2
109 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.

Age: 18Years - 130YearsAll GendersPhase 3
152 locations
S

Actively Recruiting

Researchers are studying patients with hypercholesterolaemia who either have a history of clinical atherosclerotic cardiovascular disease ASCVD or are at increased risk for a first ASCVD event. The trial aims to evaluate the effect on low-density lipoprotein-cholesterol LDL-C and the safety and tolerability of a fixed dose combination FDC of laroprovstatrosuvastatin compared to rosuvastatin alone. This is a Phase III randomized, double-blind, parallel-group study sponsored by AstraZeneca. Participants will be assigned to one of several groups receiving daily oral doses of laroprovstatrosuvastatin or rosuvastatin alone at different dose levels. Each laroprovstatrosuvastatin dose group is paired with a matching placebo to maintain blinding. The treatments are given daily over a period of 8 weeks to assess their effects on cholesterol levels. During the study, participants will undergo assessments to measure changes in LDL-C as the primary outcome at 8 weeks, along with secondary measures including Apo B, non-HDL cholesterol, and total cholesterol. Safety and tolerability will also be monitored throughout the treatment. Participants will have scheduled visits during the treatment period to ensure adherence and collect data, with the overall study completion projected by May 2027.

Age: 18Years - 130YearsAll GendersPhase 3
45 locations
E

Actively Recruiting

Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.

Age: 18Years +All GendersPhase 3
303 locations
R

Actively Recruiting

Researchers are evaluating a new medication called CX11 for people with type 2 diabetes who have not achieved good blood sugar control despite taking a steady dose of metformin, with or without an SGLT2 inhibitor, for at least 90 days. This phase 2 study involves multiple medical centers and aims to determine the effectiveness and safety of CX11 compared to placebo in adults aged 18 to 75 years with specific blood sugar and body weight criteria. Participants will be randomly assigned to one of six groups, each receiving either a different dose of CX11 tablets or a matching placebo once daily. The treatment period lasts 24 weeks, followed by a 2-week safety follow-up. Neither participants nor study staff will know which group the participant is in during the study, ensuring a double-blind design. Throughout the study, participants will undergo various assessments including blood sugar measurements like HbA1c and continuous glucose monitoring, body weight and blood pressure checks, and safety monitoring for adverse events. Blood samples will be taken at multiple time points to measure drug levels. The primary outcome is the change in HbA1c after 24 weeks of treatment. Total participation lasts approximately 26 weeks, including treatment and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
48 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
119 locations
P

Actively Recruiting

Researchers are studying the effectiveness of dotinurad compared to allopurinol in lowering serum uric acid levels in adults with tophaceous gout. This Phase 3, randomized, double-blind trial focuses on adults aged 18 to 75 years diagnosed with gout for at least one year who have measurable tophi. The study aims to evaluate how well dotinurad lowers uric acid at Week 24 compared to allopurinol. Participants are divided into two groups. One group stops their current allopurinol and takes study-provided allopurinol once daily up to Week 76. The other group stops their prior allopurinol and starts dotinurad, beginning with 1 mg daily for the first 4 weeks, increasing to 2 mg daily for 8 weeks, then 4 mg daily through Week 76. Both treatments involve oral capsules taken once a day. This approach allows comparison of the two drugs effects over an extended treatment period. During the study, participants will have regular assessments to monitor serum uric acid levels, tophi response, and gout flare frequency up to Week 80. Safety is tracked by recording any adverse events. Data collected will include changes in uric acid, tophi area, and flare rates. Participants remain in the study for over a year, with frequent visits for evaluations and treatment adherence checks.

Age: 18Years - 75YearsAll GendersPhase 3
96 locations
L

Actively Recruiting

Researchers are investigating the long-term effectiveness, safety, and tolerability of once-daily oral ASC30 compared to a placebo in adults with obesity or overweight and type 2 diabetes mellitus T2DM. This Phase III, global, randomized, double-blind, placebo-controlled study seeks to understand how different maintenance doses of ASC30 impact these participants over time. Participants will be randomly assigned to receive one of three doses of oral ASC30 tablets or matching placebo tablets once daily. The study compares these groups to evaluate the effects of ASC30 on weight and metabolic health over a 72-week period. Treatment is administered daily by mouth throughout the study. During participation, individuals will undergo regular assessments including measurements of body weight, blood sugar control HbA1c and fasting glucose, blood pressure, cholesterol, triglycerides, insulin levels, waist circumference, and body mass index. The main outcome is the percent change in body weight from the start to week 72. Safety and tolerability will be closely monitored, and the entire study duration spans about 72 weeks from baseline to final evaluation.

Age: 18Years +All GendersPhase 3
135 locations

1-10 of 34

1